What lumoslabs.com does

Lumos Labs, Inc. is a San Francisco-based private company founded in 2005 that operates a cognitive training and assessment platform under the Lumosity brand. Its core consumer product, Lumosity Brain Training, is a web- and mobile-based subscription program of 40+ game-based training tasks across cognitive domains including attention, memory, processing speed, problem solving, flexibility, and executive functioning. Daily sessions are 15 minutes across 5 games, with difficulty adapting to individual ability. Complementing this is the NeuroCognitive Performance Test (NCPT), a validated, web-based neuropsychological assessment of 17 subtests designed for at-home unsupervised use. The company runs the Human Cognition Project (HCP), a research collaboration program providing free access to its tools and de-identified datasets to 100+ qualified academic and clinical researchers; this program has produced 130+ peer-reviewed publications and currently supports 40+ ongoing studies.

The company's commercial model today is a consumer subscription for Lumosity, with research tools offered free to qualified investigators and ancillary professional services. In 2021, Lumos Labs launched Lumosity DTx, a digital therapeutics division developing prescription digital medicine for neurological and cognitive conditions. A pivotal clinical trial is underway in adult ADHD, with proof-of-concept programs across 19 clinical populations including mild cognitive impairment, stroke, Alzheimer's, cancer-related cognitive impairment, multiple sclerosis, and traumatic brain injury. The DTx division has joined the Foundation for the National Institutes of Health Biomarkers Consortium to pursue FDA-qualified digital biomarkers. The company is incorporated in the United States, headquartered in San Francisco, and serves a global footprint through web, iOS, and Android channels.

Name

lumoslabs.com

Legal name

Lumos Labs, Inc.

Website

https://lumoslabs.com

Company type

Private

Founded year

2005

Operating status

Operating

Short description

Lumos Labs operates the Lumosity consumer brain training subscription and the NeuroCognitive Performance Test (NCPT), serving individual subscribers, 100+ academic and clinical research partners via the Human Cognition Project, and developing prescription digital therapeutics through its Lumosity DTx division.

Ownership category

akta.pro rank

Product category

Cognitive Training Software

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)

akta.pro secondary industry

Medical Writing & Regulatory Submission Support CROs (HLAGAAAG)

Keywords

• Cognitive training software
• Digital therapeutics
• Neuropsychological assessment
• Brain training games
• Cognitive assessment platform

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Lumosity Consumer Subscription: Lumosity brain training program offered to consumers through subscription model, available on web and mobile platforms. The platform serves individual users who pay for access to cognitive training games.
2. Digital Therapeutics (DTx): Development of FDA-cleared digital medicine products for neurological and cognitive conditions. Pending clinical results, Lumosity DTx plans to seek FDA clearance for prescription DTx products targeting conditions such as adult ADHD.
3. Research Data Access: Through the Human Cognition Project, researchers gain access to de-identified cognitive data subsets from Lumosity or NCPT. While tools are provided free to qualified researchers, this represents data monetization through research collaborations that advance scientific understanding and product development.
4. Research Services: Lumos Labs scientists provide support on study design, data analysis, secure data storage, and regular delivery of study data for research collaborators.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Lumos Labs develops and operates Lumosity, a web and mobile cognitive training platform offering more than 40 brain training games spanning memory, attention, and problem solving domains. The company also provides the NeuroCognitive Performance Test (NCPT), a validated web-based neuropsychological assessment, and offers de-identified cognitive datasets plus paid research collaboration services (study design, data analysis, secure storage, data delivery) through the Human Cognition Project (HCP). The Lumosity DTx division develops prescription digital therapeutics for neurological conditions, with a pivotal clinical trial underway for adult ADHD.

Product overview

Lumos Labs operates a platform-plus-services model centered on cognitive training and assessment. The core product is Lumosity Brain Training, a program of 40+ cognitive games that adapt to individual ability levels. Complementing this is the NeuroCognitive Performance Test (NCPT), a validated web-based neuropsychological assessment with 17 subtests. The Human Cognition Project (HCP) provides researchers access to Lumosity software and historical datasets for academic studies. In 2021, the company launched Lumosity DTx as a new division focused on developing FDA-regulated digital therapeutics, with a pivotal clinical trial underway for adult ADHD treatment and proof-of-concept programs for conditions including MCI, stroke, and Alzheimer's Disease.

Differentiator

Problem solved

Functional benefit

Brands

• Lumosity: Brain training program including 40+ game-based training tasks spanning cognitive domains such as Attention, Memory, and Problem Solving.
• Lumosity DTx
• Human Cognition Project (HCP)
• NeuroCognitive Performance Test (NCPT)

Products and services

• Lumosity Brain Training A cognitive training program with more than 40 game-based training tasks spanning cognitive domains including Attention, Memory, Problem Solving, Cognitive Flexibility, Processing Speed, and Executive Functioning. Training consists of 15-minute daily sessions with 5 games each day, with difficulty adapting to individual abilities. Distributed via web and mobile apps to individual consumers.
• NeuroCognitive Performance Test (NCPT) A validated, brief, repeatable, modular, online neuropsychological assessment platform designed by Lumos Labs for at-home, unsupervised use through a web browser. Includes 17 subtests based on well-known neuropsychological assessments measuring memory, processing speed, reasoning, attention, and cognitive flexibility. Can be administered in clinical settings.
• Lumosity DTx Digital therapeutics division developing prescription DTx products for neurological and cognitive conditions. Currently conducting pivotal clinical trial for adult ADHD treatment, with proof-of-concept programs for MCI, stroke, Alzheimer's, cancer-related cognitive impairment, multiple sclerosis, TBI, ASD, PTSD, and schizophrenia.

Quantifiable outcome

• 130+ peer-reviewed articles from research collaborations
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Foundation for the National Institutes of Health (FNIH) Biomarkers ConsortiumcoreStrategic or Co-development PartnerLumosity DTx has joined the FNIH Biomarkers Consortium to conduct research toward the development of FDA-qualified digital biomarkers. This partnership supports the company's digital medicine initiatives and regulatory qualification efforts for quantitative behavioral measures used in predicting, diagnosing, or monitoring medical conditions.
• Human Cognition Project Research CollaboratorscoreStrategic or Co-development Partner100+ research partners across academic institutions and clinical settings participating in the Human Cognition Project. Researchers gain access to Lumosity tools, cognitive assessments, and de-identified datasets to conduct studies across disciplines including epidemiology, economics, clinical psychology, and educational psychology.
• Clinical Research InstitutionscoreStrategic or Co-development PartnerCollaborations with clinical research institutions studying populations including those with multiple sclerosis, Alzheimer's and other dementias, depression, cancer survivors, and other clinical conditions. Studies encompass both healthy and clinical populations of all ages.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Click Therapeutics: Prescription digital therapeutics company developing software-based treatments across neurology, psychiatry, and cardiometabolic indications. Closely comparable to Lumosity DTx in business model (prescription DTx) and clinical focus (neurological and mental health conditions).
• Pear Therapeutics: Pioneering prescription digital therapeutics company (reSET, reSET-O, Pear-008) that filed for bankruptcy in 2023. Historically the most prominent pure-play DTx peer to Lumosity DTx; remains a relevant benchmark for regulatory pathway, reimbursement risk, and the structural challenges of the category.
• NeuroNation: Consumer brain training app offering personalized cognitive exercises in memory, attention, and reasoning. Direct competitor to consumer Lumosity with similar product, target user, and subscription-based business model.
• CogniFit: Provider of cognitive assessment and brain training software for consumers, clinicians, and researchers. Overlaps directly with both Lumosity Brain Training and the NCPT on assessment functionality and research-grade cognitive measurement.
• Akili Interactive: Digital therapeutics company best known for EndeavorRx, an FDA-cleared prescription video game treatment for pediatric ADHD. Direct competitor to Lumosity DTx in the cognitive/neurological DTx space and the most analogous peer for the adult ADHD pivotal trial.
• Cambridge Cognition: Developer of validated computerized cognitive assessments (e.g., CANTAB) used in clinical trials and by healthcare providers. Direct competitor to NCPT in the neuropsychological assessment market and a relevant peer for digital biomarker commercialization.
• Elevate Labs: Mobile brain training app with daily cognitive exercises across math, reading, writing, and memory. Direct competitor in the consumer subscription brain-training category with overlapping audience and game-based training format.
• Posit Science (BrainHQ): Cognitive training platform with clinically validated brain exercises across memory, attention, and processing speed. Closest direct peer to consumer Lumosity and to the broader scientific brain-training category, with similar positioning around peer-reviewed efficacy.

Emerging players

• Big Health: Digital therapeutics company delivering FDA-cleared software for insomnia (Sleepio) and anxiety, with payer and employer distribution. Comparable DTx peer in clinical-grade cognitive/behavioral software and the same prescription/reimbursement go-to-market that Lumosity DTx is pursuing.
• Headspace Health: Digital mental health company combining consumer meditation content with clinician-led therapy and emerging clinical-grade mental health programs. Adjacent peer with overlap in consumer cognitive/wellness subscription and the broader digital mental health DTx category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about lumoslabs.com